While the industry floods the bloodstream with systemic molecules, Biosortia speaks nature’s own language. We harness billions of years of evolutionary optimization through pharmacological geofencing — gut-restricted, polypharmacologic small molecules that engage the full five-node gut-brain-immune axis.
Biosortia’s molecules are approached as evolutionarily informed starting points: biologically shaped chemistry that may improve early prioritization, reduce discovery friction, and support more efficient de-risking before partner diligence and formal development.
Current weight-loss and metabolic drugs rely on a simple two-node model that floods the entire body. The result? Side effects, tolerability issues, and limited real-world success.
Everywhere. Non-specific. Side-effect burden.
Gut-restricted. Multi-node signaling. Better design logic.
Biosortia’s proprietary Industrial-Scale Microbiome Mining (ISMM) platform unlocks nature’s hidden chemical signals at kilogram-to-ton scale — the only technology that delivers intact, community-derived small molecules pre-optimized by evolution.
DiscoverMicrobiome communities
ScaleIndustrial recovery
IsolateIntact small molecules
OptimizePrioritize signals
Lead franchise: Obesity / Metabolic Disease (BSP1-WL)
Expansion areas: Local GI TNF modulation (IBD), peripheral gut-brain neuromodulation (CNS), plus active discovery in oncology, pain, and anti-infectives.
Biosortia’s thesis is that microbiome-derived small molecules are not random chemistry. They are biologically shaped signals refined by evolutionary pressure inside complex living systems. That makes them compelling starting points for rapid triage, focused optimization, and partner-ready de-risking.
Evolutionarily informed molecules may begin closer to real signaling biology than purely random synthetic libraries.
Nature-mined chemistry can create a more focused search space for BiosortAI prioritization, structure refinement, and early assay selection.
The goal is to move quickly from hidden natural signals to wet validation, safety panels, PK/gut-restriction evidence, and partner diligence.
When supported by data, biologically shaped starting points may improve confidence in mechanism, optimization strategy, and development prioritization.
“Within ten years, most therapeutic pipelines will trace back to the untapped chemistry of the microbiome. Biosortia is building that future today.”